Loading…

Sign up or log in to bookmark your favorites and sync them to your phone or calendar.

Tuesday, March 15
 

7:45am PDT

Registration and Networking Breakfast
Tuesday March 15, 2022 7:45am - 8:45am PDT

8:45am PDT

Chairperson’s Opening Remarks
Speakers
avatar for Michael Myers

Michael Myers

Sr. Director - Lilly Research Labs, Due Diligence, Eli Lilly
Dr. Mike Myers has worked >30 years in pharma and has spent his career contributing to the discovery and development of new drugs.  He is an inventor on 35 patents and has led teams in the pursuit of innovative treatments for cancer, CNS, infectious and cardiovascular disease.  Mike... Read More →


Tuesday March 15, 2022 8:45am - 9:00am PDT

9:00am PDT

Interactive Opening Roundtable Discussion: We Used to Travel to Negotiate (Difficult) Terms – Best Practices Learned During a Pandemic
This conversational style group discussion will serve as an opportunity for attendees to interact with and learn from their colleagues and benchmark their practices in accordance with other organizations and industry standards.

Tuesday March 15, 2022 9:00am - 9:45am PDT

9:45am PDT

Panel: Establish an Integrated and Optimized BD&L Process to Maximize the Value and Success of the Deal
  • Engaging the right team to ensure you get real cross functional feedback
  • Develop strategies to get the most out of your team during the entire BD&L process
  • Define the roles, responsibilities and efforts of each function during various parts of the lifecycle of the deal
  • How to identify and interact with the key decision-makers, including board members, to streamline the deal-making process
  • Making the difficult decision to kill an internal program in favor of a new product – what are the trade-offs?

Moderators
avatar for Ravi Kiron

Ravi Kiron

Head, BioPharma External Innovation, EMD Serono, Inc.
Dr. Ravi Kiron based in California, USA is an experienced pharma/biotech executive with decades of experience in discovery R&D through late-stage clinical development, intellectual property and regulatory, technology & business development, M&A, strategy and product commercialization... Read More →

Speakers
avatar for Neil Berkley

Neil Berkley

Chief Business Officer, AbCellera
Neil Berkley is Chief Business Officer at AbCellera. He has twenty plus years of corporate development, business development, and strategic planning experience in large pharma, midsize biotech/specialty pharma and small biotech companies. He has completed a wide variety of transactions... Read More →
avatar for Ariel Jasie

Ariel Jasie

Chief Business Officer, General Counsel, & Corporate Secretary, eGENESIS, INC.
Before eGenesis, Mr. Jasie most recently worked at Dermavant Sciences where he served as the chief business and strategy officer. At Dermavant, he initiated and led business development interactions for both in- and out-licensing efforts, as well as oversaw cross functional teams... Read More →
avatar for Ramlah Nehring, Ph.D.

Ramlah Nehring, Ph.D.

Head of Strategy and Transactions, Roche Diagnostics
Ramlah Nehring, Ph.D. is the Head of Strategy and Transactions at Roche Diagnostics, she is based in San Diego, California and leads a global team across APAC, North America and Europe. Her team leads deals for Roche Diagnostics across the spectrum of partnerships, licensing, and... Read More →


Tuesday March 15, 2022 9:45am - 10:30am PDT

10:30am PDT

Networking Break
Tuesday March 15, 2022 10:30am - 11:00am PDT

11:00am PDT

Panel: Choosing the Right Business Partner that Aligns with the Company’s Goals
  • Understand the drivers behind the deal and how organizations set innovation priorities
  • Analyze and prioritize different growth opportunities based on the company’s overall business development strategy
  • Evaluate different operating models for search and evaluation
  • Factors to take into consideration when selecting a partner

Moderators
avatar for Chris DeRespino

Chris DeRespino

Chief Business Officer, 3T Biosciences
Chris DeRespino serves as chief business officer at 3T Biosciences, an industry leader in TCR targeting and therapeutics discovery. In this role, Mr. DeRespino is responsible for leading business development and corporate strategy. Previously, Mr. DeRespino was CBO and acting chief... Read More →

Speakers
avatar for Lesley Stolz

Lesley Stolz

Regional Vice President, Early Innovation Partnering, Johnson & Johnson Innovation
Lesley is Regional Vice President, Early Innovation Partnering at Johnson & Johnson Innovation, California. In this role, she leads identification, incubation, due diligence, negotiation, execution and on-boarding for high-impact partnerships and collaborations in external innovation... Read More →
avatar for David Brower

David Brower

Senior Vice President, Business Development and Portfolio Strategy, Accent Therapeutics, Inc.
David Brower joined Accent in September 2018 and serves as Senior Vice President of Business Development & Portfolio Strategy. David has held a number of life science business development, strategy, and investing roles prior to joining Accent. Most recently, David led the business... Read More →
avatar for Tara Nickerson

Tara Nickerson

Chief Business Officer, Maze Therapeutics
Chief Business Officer of Maze Therapeutics, a biopharmaceutical company focused on translating genetic insights into new precision medicines. Tara was previously Chief Business Officer at Prothena Corporation (Nasdaq: PRTA) and was on the core team that formed Prothena as a public... Read More →
avatar for Craig Farrell

Craig Farrell

GTM Director, Life Sciences, AlphaSense
Craig Farrell is a member of the Go-To-Market Strategy team at AlphaSense with responsibilities for both the Life Science vertical, as well as the enterprise search offering termed Internal Insights. He began his career in a Molecular Cytology research lab at Memorial Sloan Kettering... Read More →


Tuesday March 15, 2022 11:00am - 11:45am PDT

11:45am PDT

From Uncertainty to Value Generator: Using Risk to Identify BD Opportunities
One of the most critical assumptions impacting deal valuations in life sciences is the probability of success (POS) – the likelihood an asset will progress through development to approval. Companies have long viewed this as a critical assumption in evaluating potential business development opportunities. Historically, most companies and investors have focused their use of this risk assessment to measuring subsequent event likelihood or downside potential. However, recent improvements in the quality of data, analytical techniques, and underlying technology have the potential to uncover new BD opportunities where the market may have “mispriced” risk – where applying novel approaches may increase our fidelity on projecting success rate and therefore value.

We analyzed the variances in sources and methodologies for assessing development risk and impact on asset valuations, as well as whether “risk arbitrage” might exist to uncover undervalued opportunities. In our session, we will review our findings and share a perspective on how companies and investors can utilize risk assessment as a competitive advantage in screening and valuing life science deals.

Speakers
avatar for Cody Powers

Cody Powers

Principal, ZS Associates
Cody is a principal in ZS’s New York office, focused on early stage commercial development, business development and M&A, and franchise growth strategy. He has over nine years of experience in healthcare and life sciences consulting across a range of strategy issues, including early... Read More →


Tuesday March 15, 2022 11:45am - 12:15pm PDT

12:15pm PDT

Networking Lunch
Tuesday March 15, 2022 12:15pm - 1:15pm PDT

1:15pm PDT

Panel: Exploring Innovative and Alternative Deal Structures to Mitigate Risk
  • How do you decide what the “right” deal structure is for the collaboration?
  • Building flexibility into the deal structure
  • Managing uncertainty: Different structures, goals and valuations for early vs. late stage deals
  • Deciding whether to go the M&A route vs. alliances or product acquisition
  • Going beyond the conventional: Examples of innovative deal structures: joint ventures, subsidiary programs, non-equity structures, royalty financing and more


Moderators
avatar for Mark Stead

Mark Stead

Senior Director in Business Development, Exelixis
Mark Stead, Ph.D. is Senior Business Development Director at Exelixis, Inc. In this role, he is responsible for the negotiation of partnerships and strategic transactions in support of Exelixis’ mission to accelerate the discovery, development and commercialization of... Read More →

Speakers
avatar for Scott Saywell

Scott Saywell

Chief Business Officer, Herophilus
Scott Saywell is the Chief Business Officer at Herophilus, a San Francisco-based neurotherapeutics company focused on curing brain diseases with its proprietary technology platform based on in vitro human tissue models.  Scott has over twenty-five years of experience in the biotech... Read More →
avatar for Karen Martell

Karen Martell

Transaction Lead - Biologics Discovery California, Bristol-Myers Squibb
Karen has over twenty-five years of business development, venture investment and scientific experience in the biopharma industry. She is based at the Redwood City, California site of Bristol-Myers Squibb where she structures, negotiates, and executes transactions with discovery-stage... Read More →


Tuesday March 15, 2022 1:15pm - 2:00pm PDT

2:00pm PDT

Panel: Global Partnerships: Special Considerations and Risks when Collaborating Abroad
  • How to avoid the common pitfalls associated with international deals
  • New trends in global partnerships: cross border deals and ex-US partnering
  • Incorporating a global market access view into the assessment
  • Structuring territorials and regional deals
  • Navigating the landscape in China: Opportunities and risks

Speakers
avatar for Adam Kundzewicz, Ph.D.

Adam Kundzewicz, Ph.D.

Global Head of Strategic Market Access Initiatives, Boehringer Ingelheim
Adam is currently working within the Corporate Market Access, Customer Value Group at Boehringer Ingelheim in Ingelheim, Germany, as a Head of Strategic Market Access Initiatives. In his role he is responsible for orchestrating and piloting the strategic customer collaboration initiatives... Read More →
avatar for Markus Decker, PhD

Markus Decker, PhD

Global Head of S&E, Oncology & CGT, Simcere Pharmaceutical Group
Markus is and experienced BD/Search & Evaluation professional with postdoctoral training and expertise in discovery and research and development in oncology, as well as possessing licensing deal experience. He has an extensive external network in the biopharmaceutical community.Prior... Read More →
avatar for John Adamou

John Adamou

Chief Business Officer, CSPC Pharmaceutical Group | Conjupro Biotherapeutics, Inc
John Adamou is Chief Business Officer, CSPC Pharmaceutical Group US. In this role, he leads the strategic partnering initiatives and activities and responsible for business development including search and evaluation, transactions, and alliance management across various therapeutic... Read More →


Tuesday March 15, 2022 2:00pm - 2:45pm PDT

2:45pm PDT

Speed Business Networking Break
Grab your business cards and connect with other attendees during this structured networking break.  Attendees will have the opportunity to meet with multiple professionals one-on-one to exchange information and discuss partnering opportunities and interests.


Tuesday March 15, 2022 2:45pm - 3:45pm PDT

3:45pm PDT

SPAC Spotlight: Assessing the Viability and Future of SPACs in Life Sciences
Speakers
avatar for William Pedranti

William Pedranti

Partner, PENG Life Science Ventures
Will is a Partner in PENG Life Science Ventures.  He is an executive and entrepreneur who has co-founded multiple companies. Will was most recently the President, Operations for Scilex Pharmaceuticals, a company which he co-founded and launched a prescription non-opioid drug for... Read More →


Tuesday March 15, 2022 3:45pm - 4:15pm PDT

4:15pm PDT

Panel: Who has Leverage? Evaluating the Current Financial Climate and How this Impacts Deal Negotiation
Moderators
avatar for Jennifer Friel Goldstein

Jennifer Friel Goldstein

Managing Partner, Life Sciences & Healthcare, SVB Capital, Silicon Valley Bank
Jennifer Friel Goldstein is the Managing Partner for Life Science & Healthcare at SVB Capital and a founding member of Venture Forward, a non-profit that provides resources and education towards developing a diverse, equitable, and inclusive venture ecosystem. She is... Read More →

Speakers
avatar for Laura Berner

Laura Berner

Chief Business Officer, TRexBio
Laura Berner brings extensive experience in corporate development, corporate and strategic transactions, investor relations, strategy and operations to her role as Chief Business Officer of TRexBio.  Prior to TRex, she was VP, Head of Business Development & Investor Relations at... Read More →
avatar for William Jakobowski

William Jakobowski

Director, Business Development & Licensing, Merck
Bill serves as Executive Director for Merck’s BD&L Pacific Innovation Hub which encompasses the North American West Coast and Asia Pacific. His responsibilities include structuring and negotiating partnerships with companies that offer differentiated early-stage therapeutic opportunities... Read More →


Tuesday March 15, 2022 4:15pm - 5:00pm PDT

5:00pm PDT

Chairperson's Closing Remarks
Tuesday March 15, 2022 5:00pm - 5:15pm PDT

5:15pm PDT

Networking Cocktail Reception
Tuesday March 15, 2022 5:15pm - 6:15pm PDT
 
Wednesday, March 16
 

8:30am PDT

Networking Breakfast
Wednesday March 16, 2022 8:30am - 9:00am PDT

9:00am PDT

Chairperson’s Opening Remarks
Speakers
avatar for Michael Myers

Michael Myers

Sr. Director - Lilly Research Labs, Due Diligence, Eli Lilly
Dr. Mike Myers has worked >30 years in pharma and has spent his career contributing to the discovery and development of new drugs.  He is an inventor on 35 patents and has led teams in the pursuit of innovative treatments for cancer, CNS, infectious and cardiovascular disease.  Mike... Read More →


Wednesday March 16, 2022 9:00am - 9:15am PDT

9:15am PDT

Interactive Opening Roundtable Discussion: We Used to Travel for Diligence – Thoughts on Optimizing the Travel Option Post-Pandemic
This conversational style group discussion will serve as an opportunity for attendees to interact with and learn from their colleagues and benchmark their practices in accordance with other organizations and industry standards.

Wednesday March 16, 2022 9:15am - 10:00am PDT

10:00am PDT

Where is the Money? Developing Hot Therapeutic Areas and Trends to Watch in 2022
Speakers
avatar for Mariana Mihalusova

Mariana Mihalusova

Vice President, Venrock
Mariana Mihalusova focuses on biotech and pharmaceutical investments, and is currently a Board Observer at Mythic Therapeutics and Ocelot Bio. Mariana brings to Venrock deep experience spanning the entire spectrum of drug development – from preclinical, to marketing approval, to... Read More →


Wednesday March 16, 2022 10:00am - 10:30am PDT

10:30am PDT

Networking Break
Wednesday March 16, 2022 10:30am - 11:00am PDT

11:00am PDT

Presentation: Ways to Navigate Bias for Informing Deal
Speakers
avatar for Michael Myers

Michael Myers

Sr. Director - Lilly Research Labs, Due Diligence, Eli Lilly
Dr. Mike Myers has worked >30 years in pharma and has spent his career contributing to the discovery and development of new drugs.  He is an inventor on 35 patents and has led teams in the pursuit of innovative treatments for cancer, CNS, infectious and cardiovascular disease.  Mike... Read More →


Wednesday March 16, 2022 11:00am - 11:30am PDT

11:30am PDT

Maximize Your Asset’s Potential Value for Deal Making: A Case Study of NT-I7 Strategic Positioning via Clinical Collaborations with Global I-O Leaders
A key challenge for small biotech in deal making is to demonstrate convincing clinical evidence of its asset’s commercial value. This requires the assessment of how the asset’s scientific strengths could meet a significant unmet medical need, and subsequently the identification of an effective and efficient clinical development plan. Hence the asset will not only have the best chance to succeed in clinical testing but also demonstrate high commercial value along the way. In the lucrative yet highly competitive Immuno-Oncology space, combination with checkpoint blockade is highly desirable and, in many cases, an absolute necessity. This case study will discuss how NeoImmuneTech have tackled these issues via clinical collaborations with three global I-O leaders (Merck, BMS, and Roche) and succeeded in generating promising early clinical efficacy data with its long acting IL-7 asset NT-I7 to address several large business opportunities, within 18 months of first patient being dosed. Pros and cons of this approach vs. some other approaches previously taken with IDO and IL-2 assets will also be discussed.

Speakers
avatar for Samuel Zhang, PhD, MBA

Samuel Zhang, PhD, MBA

Chief Business Officer, NeoImmuneTech, Inc.
Dr. Samuel Zhang joined NeoImmuneTech in May 2019 as Chief Business Officer, bringing 18 years of industry experience across the entire drug development spectrum and the expertise of efficient value creation in biotech by integrating market insight with scientific assessment and clinical... Read More →


Wednesday March 16, 2022 11:30am - 11:45am PDT

11:45am PDT

Panel: Getting your House in Order: Strategies for Sellers to Best Prepare for a Diligence Review
  • How should a seller position their assets with confidence during the initial conversation and as the diligence review advances
  • Identify what documentation the buyer needs and preparing the relevant documentation for review
  • Building trust through transparency

Moderators
avatar for Samuel Zhang, PhD, MBA

Samuel Zhang, PhD, MBA

Chief Business Officer, NeoImmuneTech, Inc.
Dr. Samuel Zhang joined NeoImmuneTech in May 2019 as Chief Business Officer, bringing 18 years of industry experience across the entire drug development spectrum and the expertise of efficient value creation in biotech by integrating market insight with scientific assessment and clinical... Read More →

Speakers
avatar for Somjeet Dey

Somjeet Dey

Business Development and Alliance Management, Otsuka America Pharmaceutical, Inc.
Somjeet has been working with Otsuka’s Global Business Development department since 2013, and he presently leads due diligence and deal negotiations for the company’s US affiliates. An ardent believer in Otsuka’s “big venture” spirit, Somjeet is committed to strategically... Read More →
avatar for Selina Estwick

Selina Estwick

Sr. Manager-External Innovation, Eli Lilly and Company
Selina Estwick has 15+ years of Life Science experience. At Eli Lilly, she leads and manages external programs throughout the drug development lifecycle; delivers critical technical transfer support, leads diligence teams, and facilitates alliances with external partnerships. A proven... Read More →


Wednesday March 16, 2022 11:45am - 12:30pm PDT

12:30pm PDT

Networking Lunch
Wednesday March 16, 2022 12:30pm - 1:30pm PDT

1:30pm PDT

Panel: Conducting a Thorough and Effective IP Due Diligence Review: Uncovering the IP Issues that can Derail the Deal
  • Overview of the current status of IP law – what new areas to look out for
  • Conducting cost-effective FTO searches
  • Identifying any ownership conflicts or infringement risks
  • Ways to address the IP problems to save the deal
  • Making a patent portfolio attractive to buyers
  • Patent term extensions and exclusivity analysis
  • Bayh-Dole considerations
Impact of the IP analysis on valuation

Speakers
avatar for Forrester Liddle

Forrester Liddle

Vice President, Intellectual Property and Contracts, Jounce Therapeutics, Inc.
avatar for William Coppola

William Coppola

Vice President, Intellectual Property, Aerie Pharmaceuticals
Bill joined Aerie Pharmaceuticals as Intellectual Property Counsel June 2018, after spending 17 years at Sanofi, and before that, in private practice.   Bill has 25 years of experience representing clients regarding a wide spectrum of patent and intellectual property matters, including... Read More →


Wednesday March 16, 2022 1:30pm - 2:15pm PDT

2:15pm PDT

Panel: Drafting and Negotiating Key Contract Terms to Minimize Future Risks
  • Working with the BD&L team to ensure that the terms included in the agreement can be executed
  • Tailoring the terms to the specific goals and type of the deal
  • Identifying the most complicated and problematic parts of the contract process and  best practices for proactively addressing them
  • Adapting critical contract terms based on the deal structure and to ensure the success of the alliance
    • Termination and force majeure clauses
    • Reps and Warranties
    • Governance
    • Milestones and reporting requirements
    • Indemnification

Speakers
avatar for Gary Loeb

Gary Loeb

General Counsel, Mammoth Biosciences
Gary Loeb is General Counsel at Mammoth Biosciences. Prior to Mammoth, he was Executive Vice President, General Counsel and Chief Compliance Officer for both Sangamo Therapeutics (genomic medicines) and Achaogen (anti-infectives). Prior to that he was Chief Business Officer and General... Read More →
avatar for Matthew Batters

Matthew Batters

General Counsel and Secretary, Arvinas
Mr. Batters is Senior Vice President, General Counsel at Arvinas, Inc. and is responsible for Arvinas’s legal, compliance and alliance management functions. Previously, Mr. Batters held positions of increasing responsibility in the legal team at Alexion Pharmaceuticals, where he led... Read More →
avatar for Jennifer Halbleib

Jennifer Halbleib

Senior Counsel, Legal Pharma Partnering, Genentech, Inc.
Jennifer is a member of the Legal Pharma Partnering group at Roche, where she specializes in structuring, drafting, and negotiating strategic collaborations, as well as supporting these collaborations following execution. Prior to joining Roche, she was a life sciences transactional... Read More →


Wednesday March 16, 2022 2:15pm - 3:00pm PDT

3:00pm PDT

Chairperson's Closing Remarks
Wednesday March 16, 2022 3:00pm - 3:15pm PDT